ILLUMINA, INC.

ILMN Nasdaq CIK: 0001110803

Company Information

Industry Laboratory Analytical Instruments
SIC Code 3826
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 5200 ILLUMINA WAY, SAN DIEGO, CA, 92122
Mailing Address 5200 ILLUMINA WAY, SAN DIEGO, CA, 92122
Phone 8582024500
Fiscal Year End 1228
EIN 330804655

Financial Overview

FY2025

$850.00M
Net Income
$6.64B
Total Assets

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report February 12, 2026 View on SEC
4 Insider stock transaction report February 11, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
8-K Current report of material events January 30, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
8-K Current report of material events January 8, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC
4 Insider stock transaction report December 16, 2025 View on SEC
4 Insider stock transaction report December 9, 2025 View on SEC
8-K Current report of material events November 25, 2025 View on SEC

Annual Reports

10-K February 12, 2026
  • Leads the global genomics market with advanced sequencing technology and a broad installed base.
  • Successfully divested GRAIL, refocusing on its core genomics business and reducing regulatory uncertainty.
View Analysis

Material Events

8-K Acquisition January 30, 2026
High Impact
  • Illumina enters the rapidly expanding proteomics market with a strategic acquisition.
  • Positions Illumina as a leader in 'multi-omics' by integrating genomics and proteomics.
View Analysis

Insider Trading

SELL 3 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3826)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.